Comparative analysis of PD‐1 target engagement of dostarlimab and pembrolizumab in advanced solid tumors using ex vivo IL‐2 stimulation data

Dostarlimab (JEMPERLI) is an anti‐programmed cell death protein‐1 (PD‐1) monoclonal antibody (mAb) which is approved by the US Food and Drug Administration for patients with recurrent/advanced mismatch repair‐deficient solid tumors, including endometrial cancer, following progression on prior treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Austin, Daren, Melhem, Murad, Gandhi, Yash, Lu, Sharon, Visser, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835122/
https://www.ncbi.nlm.nih.gov/pubmed/36317409
http://dx.doi.org/10.1002/psp4.12878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835122/
https://www.ncbi.nlm.nih.gov/pubmed/36317409
http://dx.doi.org/10.1002/psp4.12878

Ejemplares similares